Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to Yuce Sari et al.
Spampinato S, Fokdal LU, Pötter R, Haie-Meder C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van der Steen-Banasik E, Van Limbergen E, Sundset M, Westerveld H, Nout RA, Jensen NBK, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group. Spampinato S, et al. Among authors: potter r. Radiother Oncol. 2021 May;158:323-324. doi: 10.1016/j.radonc.2021.02.022. Epub 2021 Feb 26. Radiother Oncol. 2021. PMID: 33647355 No abstract available.
Prescribing, recording, and reporting in endovascular brachytherapy. Quality assurance, equipment, personnel and education.
Pötter R, Van Limbergen E, Dries W, Popowski Y, Coen V, Fellner C, Georg D, Kirisits C, Levendag P, Marijnissen H, Marsiglia H, Mazeron JJ, Pokrajac B, Scalliet P, Tamburini V; EVA(endovascular) GEC (Groupe Europeen de Curietherapie) ESTRO (European Society for Therapeutic Radiation Oncology) Working Group. Pötter R, et al. Radiother Oncol. 2001 Jun;59(3):339-60. doi: 10.1016/s0167-8140(00)00335-2. Radiother Oncol. 2001. PMID: 11369077
Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer.
Resch A, Pötter R, Van Limbergen E, Biber E, Klein T, Fellner C, Handl-Zeller L, Langbauer G, Schürer-Waldheim H, Staffen A, Jakesz R, Kubista E, Lehr S, Seitz W. Resch A, et al. Among authors: potter r. Radiother Oncol. 2002 Apr;63(1):47-58. doi: 10.1016/s0167-8140(02)00022-1. Radiother Oncol. 2002. PMID: 12065103
1,135 results